David A. Siegel Eiger Bio Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$1.02 - $7.48 $20,298 - $148,852	19,900 Added 76.99%	45,746 $53,000
Q3 2022 Nov 14, 2022	BUY	$6.04 - $9.66 $94,501 - $151,140	15,646 Added 153.39%	25,846 $195,000
Q2 2022 Aug 15, 2022	SELL	$4.99 - $8.96 $8,982 - $16,128	-1,800 Reduced 15.0%	10,200 $64,000
Q1 2022 May 16, 2022	SELL	$3.84 - $9.74 $82,352 - $208,884	-21,446 Reduced 64.12%	12,000 $100,000
Q4 2021 Feb 14, 2022	SELL	$5.12 - $8.19 $395,740 - $633,029	-77,293 Reduced 69.8%	33,446 $174,000
Q3 2021 Nov 15, 2021	SELL	$6.68 - $9.1 $434,200 - $591,500	-65,000 Reduced 36.99%	110,739 $740,000
Q2 2021 Aug 16, 2021	SELL	$7.82 - $9.23 $1.28 Million - $1.51 Million	-163,800 Reduced 48.24%	175,739 $1.5 Million
Q1 2021 May 17, 2021	SELL	$8.44 - $12.66 $431,284 - $646,926	-51,100 Reduced 13.08%	339,539 $3.01 Million
Q4 2020 Feb 16, 2021	BUY	$7.98 - $12.29 $513,114 - $790,247	64,300 Added 19.7%	390,639 $4.8 Million
Q3 2020 Nov 16, 2020	BUY	$7.96 - $12.42 $475,212 - $741,474	59,700 Added 22.39%	326,339 $2.66 Million
Q2 2020 Aug 14, 2020	BUY	$5.4 - $13.37 $216,540 - $536,137	40,100 Added 17.7%	266,639 $2.56 Million
Q1 2020 May 15, 2020	BUY	$4.91 - $14.7 $760,559 - $2.28 Million	154,900 Added 216.22%	226,539 $1.54 Million
Q4 2019 Feb 14, 2020	BUY	$9.77 - $15.66 $531,488 - $851,904	54,400 Added 315.56%	71,639 $1.07 Million
Q3 2019 Nov 14, 2019	SELL	$9.59 - $12.0 $80,556 - $100,800	-8,400 Reduced 32.76%	17,239 $177,000
Q2 2019 Aug 14, 2019	BUY	$9.54 - $14.96 $81,090 - $127,160	8,500 Added 49.59%	25,639 $272,000
Q1 2019 May 15, 2019	BUY	$10.31 - $14.38 $176,703 - $246,458	17,139 New	17,139 $240,000

Others Institutions Holding EIGR

# of Institutions

Shares Held

748K

Call Options Held

Put Options Held

View Full List

About Eiger BioPharmaceuticals, Inc.

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

More about EIGR

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account